Menu Search
Equities

Avadel Pharmaceuticals PLC

AWK:DUS

Avadel Pharmaceuticals PLC

Actions
  • Price (EUR)11.90
  • Today's Change-0.20 / -1.65%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 08:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Avadel Pharmaceuticals PLC's net income fell 16.59% from a loss of 137.46m to a larger loss of 160.28m despite revenues that grew -- from 0.00 to 27.96m.
Gross margin94.62%
Net profit margin-111.64%
Operating margin-103.82%
Return on assets-59.26%
Return on equity-99.54%
Return on investment-80.97%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Avadel Pharmaceuticals PLC fell by 42.81m. Cash Flow from Financing totalled 135.34m or 483.98% of revenues. In addition the company used 128.51m for operations while cash used for investing totalled 50.09m.
Cash flow per share-1.14
Price/Cash flow per share--
Book value per share0.7306
Tangible book value per share0.5556
More ▼

Balance sheet in USDView more

Avadel Pharmaceuticals PLC uses little or no debt in its capital structure.
Current ratio2.82
Quick ratio2.52
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.